http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 22 Apr 2026 07:01:58 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Actinium+reports+ATNM-400+cancer+therapy+data+at+AACR+meeting/26347061.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) presented preclinical data for its ATNM-400 targeted radiotherapy at the American Association for Cancer Research Annual Meeting in San Diego. The experimental treatment showed activity across prostate, lung, and breast cancer models in laboratory studies.</p><p>ATNM-400 uses the Actinium-225 radioisotope and targets a membrane antigen that the company states is overexpressed in treatment-resistant solid tumors. In prostate cancer models, the therapy demonstrated efficacy in both high and low PSMA-expressing cancers, as well as PSMA-negative models.</p><p>The treatment showed greater tumor growth inhibition than osimertinib plus chemotherapy in EGFR-mutant non-small cell lung cancer models. The company also http://www.streetinsider.com/Corporate+News/Actinium+reports+ATNM-400+cancer+therapy+data+at+AACR+meeting/26347061.html Wed, 22 Apr 2026 07:01:58 -0400 ATNM NYSE http://www.streetinsider.com/Corporate+News/Actinium+reports+ATNM-400+cancer+therapy+data+at+AACR+meeting/26347061.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) presented preclinical data for its ATNM-400 targeted radiotherapy at the American Association for Cancer Research Annual Meeting in San Diego. The experimental treatment showed activity across prostate, lung, and breast cancer models in laboratory studies.</p><p>ATNM-400 uses the Actinium-225 radioisotope and targets a membrane antigen that the company states is overexpressed in treatment-resistant solid tumors. In prostate cancer models, the therapy demonstrated efficacy in both high and low PSMA-expressing cancers, as well as PSMA-negative models.</p><p>The treatment showed greater tumor growth inhibition than osimertinib plus chemotherapy in EGFR-mutant non-small cell lung cancer models. The company also http://www.streetinsider.com/Corporate+News/Actinium+reports+ATNM-400+cancer+therapy+data+at+AACR+meeting/26347061.html Wed, 22 Apr 2026 07:01:58 -0400 ATNM NYSE http://www.streetinsider.com/FDA/Actinium+reports+ATNM-400+cancer+therapy+data+at+AACR+meeting/26347061.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) presented preclinical data for its ATNM-400 targeted radiotherapy at the American Association for Cancer Research Annual Meeting in San Diego. The experimental treatment showed activity across prostate, lung, and breast cancer models in laboratory studies.</p><p>ATNM-400 uses the Actinium-225 radioisotope and targets a membrane antigen that the company states is overexpressed in treatment-resistant solid tumors. In prostate cancer models, the therapy demonstrated efficacy in both high and low PSMA-expressing cancers, as well as PSMA-negative models.</p><p>The treatment showed greater tumor growth inhibition than osimertinib plus chemotherapy in EGFR-mutant non-small cell lung cancer models. The company also http://www.streetinsider.com/FDA/Actinium+reports+ATNM-400+cancer+therapy+data+at+AACR+meeting/26347061.html Wed, 22 Apr 2026 07:01:58 -0400 ATNM NYSE http://www.streetinsider.com/FDA/Actinium+reports+ATNM-400+cancer+therapy+data+at+AACR+meeting/26347061.html <p>Actinium Pharmaceuticals Inc. (NYSE American: ATNM) presented preclinical data for its ATNM-400 targeted radiotherapy at the American Association for Cancer Research Annual Meeting in San Diego. The experimental treatment showed activity across prostate, lung, and breast cancer models in laboratory studies.</p><p>ATNM-400 uses the Actinium-225 radioisotope and targets a membrane antigen that the company states is overexpressed in treatment-resistant solid tumors. In prostate cancer models, the therapy demonstrated efficacy in both high and low PSMA-expressing cancers, as well as PSMA-negative models.</p><p>The treatment showed greater tumor growth inhibition than osimertinib plus chemotherapy in EGFR-mutant non-small cell lung cancer models. The company also http://www.streetinsider.com/FDA/Actinium+reports+ATNM-400+cancer+therapy+data+at+AACR+meeting/26347061.html Wed, 22 Apr 2026 07:01:58 -0400 ATNM NYSE http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/Press+Releases/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html <div class="xn-content"> <ul type="disc"><li>ATNM-400 demonstrates pan-tumor activity across prostate, lung, and breast cancer models, supporting multi-indication development potential</li><li>In prostate cancer, ATNM-400 demonstrates efficacy across both high PSMA-expressing and, importantly, low PSMA-expressing prostate cancer models, unlike many PSMA-targeted radioligand therapies that work only in PSMA-high settings</li><li>In EGFR-mutant non-small cell lung cancer, ATNM-400 demonstrates greater tumor growth inhibition than osimertinib (a tyrosine kinase inhibitor) plus chemotherapy and outperforms the approved Trop-2 ADC Dato-DXd (DATROWAY®), the EGFR-cMET bispecific antibody amivantamab (RYBREVANT®) and the experimental EGFR-HER3 ADC izalontamab brengitecan, supporting potential use across first-, second-, and third-line treatment settings</li><li>In breast cancer, new head-to-head data shows http://www.streetinsider.com/PRNewswire/Actinium+Pharmaceuticals%2C+Inc.+Announces+Compelling+Pan-Tumor+Data+for+ATNM-400+Demonstrating+Broad+Efficacy+Across+Prostate%2C+Lung%2C+and+Breast+Cancer+Models+at+the+2026+American+Association+of+Cancer+/26347012.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Highlights+Transcriptional+Reprogramming+as+a+Key+Mechanism+Underpinning+Mutation-Agnostic+Activity+of+Actimab-A+in+AML+at+the+2026+American+Association+of+Cancer+Research+Annual+Meeting/26347013.html <div class="xn-content"> <ul type="disc"><li>Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies including revumenib (menin-KMT2A inhibitor), gilteritinib (FLT3 inhibitor), and azacitidine (hypomethylating agent) - three pillars of modern AML treatment - supporting its potential role as a universal combination backbone<br /><br /></li><li>Transcriptional reprogramming identified as a central mechanism showing that Actimab-A combinations don't just add cytotoxicity, they reprogram AML cells from proliferation toward differentiation and apoptosis, providing the mechanistic basis for deeper, more durable MRD-negative responses and reinforcing Actimab-A's role as a universal combination backbone across AML<br http://www.streetinsider.com/Press+Releases/Actinium+Highlights+Transcriptional+Reprogramming+as+a+Key+Mechanism+Underpinning+Mutation-Agnostic+Activity+of+Actimab-A+in+AML+at+the+2026+American+Association+of+Cancer+Research+Annual+Meeting/26347013.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Highlights+Transcriptional+Reprogramming+as+a+Key+Mechanism+Underpinning+Mutation-Agnostic+Activity+of+Actimab-A+in+AML+at+the+2026+American+Association+of+Cancer+Research+Annual+Meeting/26347013.html <div class="xn-content"> <ul type="disc"><li>Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies including revumenib (menin-KMT2A inhibitor), gilteritinib (FLT3 inhibitor), and azacitidine (hypomethylating agent) - three pillars of modern AML treatment - supporting its potential role as a universal combination backbone<br /><br /></li><li>Transcriptional reprogramming identified as a central mechanism showing that Actimab-A combinations don't just add cytotoxicity, they reprogram AML cells from proliferation toward differentiation and apoptosis, providing the mechanistic basis for deeper, more durable MRD-negative responses and reinforcing Actimab-A's role as a universal combination backbone across AML<br http://www.streetinsider.com/Press+Releases/Actinium+Highlights+Transcriptional+Reprogramming+as+a+Key+Mechanism+Underpinning+Mutation-Agnostic+Activity+of+Actimab-A+in+AML+at+the+2026+American+Association+of+Cancer+Research+Annual+Meeting/26347013.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Highlights+Transcriptional+Reprogramming+as+a+Key+Mechanism+Underpinning+Mutation-Agnostic+Activity+of+Actimab-A+in+AML+at+the+2026+American+Association+of+Cancer+Research+Annual+Meeting/26347013.html <div class="xn-content"> <ul type="disc"><li>Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies including revumenib (menin-KMT2A inhibitor), gilteritinib (FLT3 inhibitor), and azacitidine (hypomethylating agent) - three pillars of modern AML treatment - supporting its potential role as a universal combination backbone<br /><br /></li><li>Transcriptional reprogramming identified as a central mechanism showing that Actimab-A combinations don't just add cytotoxicity, they reprogram AML cells from proliferation toward differentiation and apoptosis, providing the mechanistic basis for deeper, more durable MRD-negative responses and reinforcing Actimab-A's role as a universal combination backbone across AML<br http://www.streetinsider.com/Press+Releases/Actinium+Highlights+Transcriptional+Reprogramming+as+a+Key+Mechanism+Underpinning+Mutation-Agnostic+Activity+of+Actimab-A+in+AML+at+the+2026+American+Association+of+Cancer+Research+Annual+Meeting/26347013.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Highlights+Transcriptional+Reprogramming+as+a+Key+Mechanism+Underpinning+Mutation-Agnostic+Activity+of+Actimab-A+in+AML+at+the+2026+American+Association+of+Cancer+Research+Annual+Meeting/26347013.html <div class="xn-content"> <ul type="disc"><li>Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies including revumenib (menin-KMT2A inhibitor), gilteritinib (FLT3 inhibitor), and azacitidine (hypomethylating agent) - three pillars of modern AML treatment - supporting its potential role as a universal combination backbone<br /><br /></li><li>Transcriptional reprogramming identified as a central mechanism showing that Actimab-A combinations don't just add cytotoxicity, they reprogram AML cells from proliferation toward differentiation and apoptosis, providing the mechanistic basis for deeper, more durable MRD-negative responses and reinforcing Actimab-A's role as a universal combination backbone across AML<br http://www.streetinsider.com/Press+Releases/Actinium+Highlights+Transcriptional+Reprogramming+as+a+Key+Mechanism+Underpinning+Mutation-Agnostic+Activity+of+Actimab-A+in+AML+at+the+2026+American+Association+of+Cancer+Research+Annual+Meeting/26347013.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543 http://www.streetinsider.com/Press+Releases/Actinium+Highlights+Transcriptional+Reprogramming+as+a+Key+Mechanism+Underpinning+Mutation-Agnostic+Activity+of+Actimab-A+in+AML+at+the+2026+American+Association+of+Cancer+Research+Annual+Meeting/26347013.html <div class="xn-content"> <ul type="disc"><li>Actimab-A combinations enhanced in vivo AML cell killing across multiple preclinical models, independent of mutation status, when combined with standard-of-care targeted and non-targeted therapies including revumenib (menin-KMT2A inhibitor), gilteritinib (FLT3 inhibitor), and azacitidine (hypomethylating agent) - three pillars of modern AML treatment - supporting its potential role as a universal combination backbone<br /><br /></li><li>Transcriptional reprogramming identified as a central mechanism showing that Actimab-A combinations don't just add cytotoxicity, they reprogram AML cells from proliferation toward differentiation and apoptosis, providing the mechanistic basis for deeper, more durable MRD-negative responses and reinforcing Actimab-A's role as a universal combination backbone across AML<br http://www.streetinsider.com/Press+Releases/Actinium+Highlights+Transcriptional+Reprogramming+as+a+Key+Mechanism+Underpinning+Mutation-Agnostic+Activity+of+Actimab-A+in+AML+at+the+2026+American+Association+of+Cancer+Research+Annual+Meeting/26347013.html Wed, 22 Apr 2026 07:00:00 -0400 A.35552990 A.60001765 ATNM NYSE NYSE O.00074346 O.06705834 O.20738543